Purpose: Congenital bladder outlet obstruction from either mechanical or fu
nctional causes often results in clinical bladder fibrosis. We tested the h
ypothesis that early molecular changes relevant to fibrosis occur in respon
se to stretch injury of the bladder wall and that specific extracellular ma
trix receptors mediate some of these responses. Furthermore, we introduce a
novel ex vivo model of bladder injury which has advantages over previously
described in vivo bladder outlet obstruction models by uniquely interrogat
ing molecular responses to bladder distention.
Materials and Methods: The bladders of Sprague Dawley rats were hydrodisten
ded transurethrally, the ureters and bladder neck were ligated, and the who
le bladder was excised and incubated in culture medium in the distended sta
te. At fixed time-points control and stretch bladders were snap frozen, RNA
was extracted, and semiquantitative reverse transcription polymerase chain
reaction for collagens I, III and XII, and RHAMM (receptor for hyaluronic
acid) messenger (m) RNA was performed to establish trends in stretch relate
d gene expression. Bladder specimens were also subjected to routine histolo
gical evaluation.
Results: An average 3-fold reduction in collagen I mRNA expression was seen
with 8 hours of static stretch (p <0.05). Bladder stretch increased collag
en III mRNA levels approximately 2.5-fold (p <0.05). Whole bladder collagen
XII and RHAMM mRNA were elevated as much as Ei-fold (p <0.05) with stretch
. Blocking RHAMM function significantly attenuated these matrix gene respon
ses (p = 0.01 to 0.005).
Conclusions: The ex vivo model of whole bladder stretch is viable and easil
y reproducible for the study of molecular pathophysiological mechanisms con
tributing to maladaptive bladder disease. Furthermore, collagen gene transc
ription is revealed to be rapidly responsive to stretch injury of the bladd
er. Intact RHAMM receptor function is involved in these responses. Elucidat
ion of the intermediate steps in this response to injury may allow for the
development of novel therapeutic strategies which may prevent pathological
matrix remodeling seen in clinical bladder disease.